Dr. Straubinger received dual B.A. degrees in English and Anthropology from the University of Rochester, the M.S. degree in Natural Sciences from the Roswell Park division of the University at Buffalo/SUNY, and the Ph.D. in Pharmacology from the University of California at San Francisco. He was a postdoctoral fellow in the Cancer Research Institute and in the Cardiovascular Research Institute at the University of California, San Francisco.
Dr. Straubinger's research focuses on the broad area of drug carriers and drug delivery, with an emphasis on the mechanisms by which drug carriers alter the pharmacology of carrier-associated drugs. The research approaches include biophysical investigations of the pharmaceutical properties of drug:carrier complexes, pharmacokinetic and pharmacodynamic analysis to probe mechanisms behind the therapeutic effects of drug carriers. A major new research direction is to develop proteomic approaches, principally based on liquid chromatography/mass spectrometry (LC/MS), to identify pharmacodynamic effect 'biomarkers' to assist in the development and optimization of therapies. Current research funding focuses on mechanisms by which drug carriers can modulate tumor vascular permeability.
Dr. Straubinger also serves as director of the Pharmaceutical Sciences Instrumentation Facility, which has facilities on the UB North Campus and the UB Center of Excellence in Bioinformatics and Life Sciences Downtown Campus.
539 Cooke Hall, North Campus
Telephone: (716) 645-2844
Fax: (716) 645-3693
|UB Center of Excellence in Bioinformatics and Life Sciences|
CLICK HERE for an updated bibliograpy (limited to articles listed in the PubMed database).
You can find the full text of some published papers HERE in PubMedCentral.
1. Cao J; Gonzalez-Covarrubias V; Straubinger RM; Wang H; Duan X; Yu H; Qu J; Blanco JG. A rapid, reproducible, on-the-fly orthogonal array optimization method for targeted protein quantification by LC/MS and its application for accurate and sensitive quantification of carbonyl reductases in human liver. Analyt. Chem. 82: 2680-9 (2010).
2. Peng A; Straubinger RM; Balu-Iyer SV. Phosphatidylinositol containing lipidic particles reduce immunogenicity and catabolism of Factor VIII in Hemophilia A mice. AAPS J 12: 473-81 (2010).
3. Yang J; Mager DE; Straubinger RM. Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. AAPS J 12: 1-10 (2010).
4. Zhou R; Mazurchuk RV; Tamburlin JH; Harrold JM; Mager DE; Straubinger RM. Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model. J Pharmacol Exp Ther 332: 479-88 (2010).
5. Duan XT; Young R; Straubinger RM; Page BJ; Cao J; Wang H; Yu H; Canty JM, Jr.; Qu J. A straightforward and highly efficient precipitation/on-pellet digestion procedure coupled with a long gradient nano-LC separation and Orbitrap mass spectrometry for label-free expression profiling of the swine heart mitochondrial proteome. J Proteome Res 8: 2838-50 (2009).
6. Wang H; Straubinger RM; Aletta JM; Cao J; Duan X; Yu H; Qu J. Accurate localization and relative quantification of arginine methylation using nanoflow liquid chromatography coupled to electron transfer dissociation and orbitrap mass spectrometry. J Am Soc Mass Spectrom 20: 507-19 (2009).
7. Gaspar JR; Qu J; Straubinger NL; Straubinger RM. Highly selective and sensitive assay for paclitaxel accumulation by tumor cells based on selective solid phase extraction and micro-flow liquid chromatography coupled to mass spectrometry. Analyst 133: 1742-8 (2008).
8. Ramani K; Miclea RD; Purohit VS; Mager DE; Straubinger RM; Balu-Iyer SV. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J. Pharm. Sci. 97: 1386-98 (2008).
9. Ramani K; Purohit VS; Miclea RD; Gaitonde P; Straubinger RM; Balu-Iyer SV. Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A. J. Pharm. Sci. 97: 3753-64 (2008).
10. Yu H; Straubinger RM; Cao J; Wang HS; Qu J. Ultra-sensitive quantification of paclitaxel using selective solid-phase extraction in conjunction with reversed-phase capillary liquid chromatography/tandem mass spectrometry. J. Chromatog. A 1210: 160-7 (2008).
11. Balasubramanian SV; Straubinger RM; Ramani K; Besman M; Kashi R.Method of complexing a protein by the use of a dispersed system and proteins thereof. (Assigned to: The Research Foundation of State University of New York (1576 Sweet Home Road, Suite 111, Amherst, NY 14228, US)) (2007).
12. Drake EJ; Cao J; Qu J; Shah MB; Straubinger RM; Gulick AM. The 1.8 Å crystal structure of PA2412, an MbtH-like protein from the pyoverdine cluster of Pseudomonas aeruginosa. J. Biol. Chem. 282: 20425-34 (2007).
13. Qu J; Qu Y; Straubinger RM. Ultra-sensitive quantification of corticosteroids in plasma samples using selective solid-phase extraction and reversed-phase capillary high-performance liquid chromatography/tandem mass spectrometry. Anal Chem 79: 3786-93 (2007).
14. Straubinger RM; Krzyzanski W; Francoforte CM; Qu J. Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development. Anticancer Res. 27: 1237-46 (2007).
15. Qu J; Jusko WJ; Straubinger RM. Utility of cleavable isotope-coded affinity-tagged reagents for quantification of low-copy proteins induced by methylprednisolone using liquid chromatography/tandem mass spectrometry. Anal Chem 78: 4543-52 (2006).
16. Arnold RD; Mager DE; Slack JE; Straubinger RM. Effect of repetitive administration of doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin. Cancer Res. 11: 8856-65 (2005).
17. Qu J; Straubinger RM. Improved sensitivity for quantification of proteins using triply charged cleavable isotope-coded affinity tag peptides. Rapid Commun Mass Spect. 19: 2857-64 (2005).
18. Straubinger RM; Balasubramanian SV. Preparation and characterization of taxane-containing liposomes. In (N Düzgünes ed.), Methods in Enzymology, 391, Academic Press, New York, 2005, pp. 97-117.
19. Arnold RD; Slack JE; Straubinger RM. Quantification of doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/ electrospray tandem mass spectroscopy. J. Chromatog. B, Anl. Tech. Biomed. Life Sci. 808: 141-52 (2004).
20. Straubinger R; Arnold R; Zhou R; Mazurchuk R; Slack J. Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res. 24: 397-404 (2004).
21. Fetterly GJ; Straubinger RM. Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci 5: Article 31 (2003).
22. Almon RR; DuBois DC; Brandenburg EH; Shi W; Zhang S; Straubinger RM; Jusko WJ. Pharmacodynamics and pharmacogenomics of diverse receptor-mediated effects of methylprednisolone in rats using microarray analysis. J. Pharmacokinet. Pharmacodynam. 29: 103-29 (2002).
23. Zhou R; Mazurchuk RV; Straubinger RM. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res. 62: 2561-6 (2002).
24. Campbell RB; Balasubramanian SV; Straubinger RM. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. J. Pharm. Sci. 90: 1091-105 (2001).
25. Fetterly GJ; Tamburlin JM; Straubinger RM. Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model. Biopharm. Drug Dispos. 22: 251-61 (2001).
26. Mazurchuk R; Zhou R; Straubinger RM; Chau RI; Grossman Z. Functional magnetic resonance (fMR) imaging of a rat brain tumor model: implications for evaluation of tumor microvasculature and therapeutic response. Magn. Reson. Imag. 17: 537-48 (1999).
27. Sharma US; Sharma A; Chau RI; Straubinger RM. Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm. Res. 14: 992-8 (1997).
28. Oh Y-K; Straubinger RM. Intracellular fate of Mycobacterium avium: use of dual-label spectrofluorometry to investigate the influence of bacterial viability and opsonization on phagosomal pH and phagosome-lysosome interaction. Infect. Immun. 64: 319-25 (1996).
29. Oh Y-K; Nix DE; Straubinger RM. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular M. avium infection. Antimicrob. Agents Chemother. 39: 2104-11 (1995).
30. Sharma US; Balasubramanian SV; Straubinger RM. Pharmaceutical and physical properties of paclitaxel (taxol) complexes with cyclodextrins. J. Pharm. Sci. 84: 1223-30 (1995).
31. Straubinger RM. Biopharmaceutics of paclitaxel (taxol): formulation, activity, and pharmacokinetics. In (M Suffness ed.), Taxol. Science and Applications, CRC Press, Boca Raton, 1995, pp. 237-58.
32. Balasubramanian SV; Alderfer JL; Straubinger RM. Solvent- and concentration-dependent molecular interactions of taxol (paclitaxel). J. Pharm. Sci. 83: 1470-6 (1994).
33. Balasubramanian SV; Straubinger RM. Taxol-lipid interactions: taxol-dependent effects on the physical properties of model membranes. Biochemistry 33: 8941-7 (1994).
34. Sharma A; Conway WD; Straubinger RM. Reversed-phase high-performance liquid chromatographic determination of taxol in mouse plasma. J. Chromatog. B, Anl. Tech. Biomed. Life Sci. 655: 315-9 (1994).
35. Sharma A; Straubinger RM. Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm. Res. 11: 889-96 (1994).
36. Sharma A; Mayhew E; Straubinger RM. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res. 53: 5877-81 (1993).
37. Sharma A; Straubinger NL; Straubinger RM. Modulation of human ovarian tumor cell sensitivity to N-(Phosphonacetyl)-L-Aspartate (PALA) by liposome drug carriers. Pharm. Res. 10: 1434-41 (1993).
38. Chin DJ; Green GA; Zon G; Szoka FC, Jr.; Straubinger RM. Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biologist 2: 1091-100 (1990).
39. Straubinger RM; Papahadjopoulos D; Hong K. Endocytosis and intracellular fate of liposomes using pyranine as a probe. Biochemistry 29: 4929-39 (1990).
40. Chin DJ; Straubinger RM; Acton S; Näthke I; Brodsky FM. 100 kDa polypeptides in peripheral clathrin-coated vesicles are required for receptor-mediated endocytosis. Proc. Natl. Acad. Sci. U.S.A. 86: 9289-93 (1989).
41. Straubinger RM; Lopez NG; Debs R; Hong K; Papahadjopoulos D. Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively-charged and antibody-targeted liposomes. Cancer Res. 48: 5237-45 (1988).
42. Debs R; Straubinger RM; Brunette E; Lin J; Lin E; Papahadjopoulos D. Selective enhancement of pentamidine accumulation in the lung by administration in liposomes via aerosol and intravenous routes. Amer. Review Respiratory Dis. 135: 731-7 (1987).
43. Straubinger RM; Düzgünes N; Papahadjopoulos D. pH-Sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Letters 179: 148-54 (1985).
44. Straubinger RM; Hong K; Friend DS; Papahadjopoulos D. Endocytosis of liposomes and intracellular fate of encapsulated contents: encounter with a low-pH compartment after internalization in coated vesicles. Cell 32: 1069-79 (1983).
UB Pharmaceutics Faculty Page